Update on fingolimod Phase 3 trial in primary progressive MS
Update on fingolimod Phase 3 trial in primary progressive MS
Novartis announced today that the Phase III INFORMS study in primary progressive multiple sclerosis (PPMS) did not show a significant difference between fingolimod and placebo on a combination of disability measures. The safety results were consistent with the well-characterized safety profile of fingolimod in relapsing MS (RMS)....... Read more - http://www.ms-uk.org/gilenya
MS-UK - http://www.ms-uk.org/